In a filing, Nurix Therapeutics Inc revealed its Chief Financial Officer van Houte Hans unloaded Company’s shares for reported $68223.0 on Feb 16 ’24. In the deal valued at $10.02 per share,6,812 shares were sold. As a result of this transaction, van Houte Hans now holds 68,333 shares worth roughly $0.94 million.
Then, Hansen Gwenn sold 2,334 shares, generating $18,649 in total proceeds. Upon selling the shares at $7.99, the Chief Scientific Officer now owns 36,402 shares.
Before that, Ring Christine sold 1,760 shares. Nurix Therapeutics Inc shares valued at $14,063 were divested by the Chief Legal Officer at a price of $7.99 per share. As a result of the transaction, Ring Christine now holds 17,427 shares, worth roughly $0.24 million.
A number of analysts have revised their coverage, including Barclays’s analysts, who began to cover the stock in early March with a ‘”an Overweight”‘ rating. Oppenheimer began covering NRIX with “an Outperform” recommendation on February 28, 2023. Morgan Stanley started covering the stock on October 11, 2022. It rated NRIX as “an Equal-weight”.
Price Performance Review of NRIX
On Monday, Nurix Therapeutics Inc [NASDAQ:NRIX] saw its stock fall -0.72% to $13.80. Over the last five days, the stock has lost -5.35%. Nurix Therapeutics Inc shares have risen nearly 33.72% since the year began. Nevertheless, the stocks have risen 57.18% over the past one year. While a 52-week high of $16.11 was reached on 03/07/24, a 52-week low of $4.22 was recorded on 01/29/24. SMA at 50 days reached $11.77, while 200 days put it at $9.09. A total of 0.45 million shares were traded, compared to the trading of 0.62 million shares in the previous session.
Levels Of Support And Resistance For NRIX Stock
The 24-hour chart illustrates a support level at 13.47, which if violated will result in even more drops to 13.13. On the upside, there is a resistance level at 14.13. A further resistance level may holdings at 14.45. The Relative Strength Index (RSI) on the 14-day chart is 54.13, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.03, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 52.00%. Stochastics %K at 51.70% indicates the stock is a holding.
How much short interest is there in Nurix Therapeutics Inc?
A steep rise in short interest was recorded in Nurix Therapeutics Inc stocks on Mar 15, 2024, dropping by -0.86 million shares to a total of 6.41 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 7.27 million shares. There was a decline of -13.42%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 13.41% of the overall stock float, the days-to-cover ratio (short ratio) fell to 5.92.
